Clinical Trial

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-07; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Recruiting 2026-05-21
Trial Details
NCT Number NCT07172659
Lead Sponsor Medicines Development for Global Health
Conditions Erythema Nodosum Leprosum
Enrollment 45 participants
Start Date 2026-05-25
Primary Completion 2027-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-26